Resolute System    

Log In

Forgot Your Password?

Not a member? Click here!

Antiplatelet Effects of Anticoagulants: Potential of Oral Factor Xa Inhibitors to Prevent Arterial Thrombosis
Lessons from the ISAR REACT Studies: How Should We Anticoagulate Our Patients for PCI
Will the New Antiplatelet Agents in the Pipeline Replace Clopidogrel?
Is There a Role for Long Term Use of Clopidogrel for Primary and Secondary Prevention After CHARISMA?
ISAR REACT 2: Abciximab in Patients with ACS Undergoing PCI



Real-World Analysis Supports Target Vessel PCI in STEMI

Warfarin is the recommended therapy for patients with AF. The PROTECT-AF study, comparing warfarin with mechanical left atrial appendage closure (LAAC), has indicated that the latter is both non-inferior and superior for preventing the combined outcome of stroke, systemic embolism, and CV death.

For more, click here




Can Bivalirudin Resist the Heat?

The role of bivalirudin in PPCI has been challenged in the HEAT-PPCI study. This open-label, randomized controlled trial comparing unfractionated heparin with bivalirudin has shown that heparin reduces the incidence of major adverse ischemic events with no increased risk of bleeding.

For more, click here




Impact of Non-Culprit Lesions in STEMI Patients

Two recent randomized studies have indicated total revascularization at the index admission in patients undergoing PPCI for STEMI. A retrospective analysis of 8 randomized studies, including 28282 patients, has suggested that obstructive non-culprit disease is common in patients presenting with STEMI and associated with only a modest increase in 30-day mortality.

For more, click here




ß-Blockers in Patients With Heart Failure and Preserved Ejection Fraction

The clinical impact of ß-Blockers in patients with heart failure and preserved ejection fraction is poorly studied. A retrospective, propensity score-matched cohort study has indicated that ß-Blockers are associated with lower all-cause mortality in such patients but not with combined all-cause mortality or heart failure hospitalization.

For more, click here



Untitled Document
Minimizing Femoral Artery Access Complications during PCI
- Michael S. Lee, MD
PROTECT Trial: 5 Year Outcomes
- Edoardo Camenzind, MD
Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim 12-month results from the Global SYMPLICITY Registry
- Felix Mahfoud, MD
SYMPLICITY HTN-3 Trial: 12-month outcomes following un-blinding of subjects at 6 months
- George L. Bakris, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

Jeremiah Brown, MDBicuspid Aortic Valve and TAVI
- Eberhard Grube, MD

 Click here to visit the WEBEX archives

Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture: The ISAR-CLOSURE Randomized Clinical Trial.
S Schulz-Schüpke, et al.
JAMA 2014; 312:1981-1987
Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Clinical Trial.
V Reddy, et al.
JAMA 2014; 312:1988-1998
Association of Inpatient vs Outpatient Onset of ST-Elevation Myocardial Infarction With Treatment and Clinical Outcomes.
P Kaul, et al.
JAMA 2014; 312:1999-2007
Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
L Wallentin, et al.
Circ 2015; 130:1847-1858
Improved Survival After Out-of-Hospital Cardiac Arrest and Use of Automated External Defibrillators.
M Blom, et al.
Circ 2014; 130:1868-1875
Trends in Short- and Long-Term Survival Among Out-of-Hospital Cardiac Arrest Patients Alive at Hospital Arrival.
TM Wong, et al.
Circ 2014; 130:1883-1890
Glycemic Control and Excess Mortality in Type 1 Diabetes.
M Lind, et al.
NEJM 2014; 371:1972-1982
Unfractionated Heparin Versus Bivalirudin in Primary Percutaneous Coronary Intervention (HEAT-PPCI): An Open-Label, Single Centre, Randomised Controlled Trial.
A Shahzad, et al.
The Lancet 2014; 384:1849-1858
Incidence of Infective Endocarditis in England, 2000—13: a Secular Trend, Interrupted Time-Series Analysis.
M Dayer, et al.
The Lancet 2014 Online
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (From the Acute Catheterization and Urgent Intervention Triage Strategy Trial).
K Goto, et al.
AJC 2014; 114:1638-1645
Vorapaxar With or Without Clopidogrel After Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome Trial.
P Tricoci, et al.
AHJ 2014; 168:869-877

Poll Archives
Results from the DAPT Study
Dean J. Kereiakes, MD
Primary Outcomes of the EVOLVE II Trial
Dean J. Kereiakes, MD
Dion Stub, MD
C.Kaiser, MD, et al.
Final Results of the Regional Systems of Care Demonstration Project: Mission: Lifeline STEMI Accelerator Study
Matthew W. Sherwood, MD, et al.
Dual Antiplatelet Therapy Beyond One Year After Drug-eluting Coronary Stent Procedures
Laura Mauri, MD, et al.
Randomized Trial of Atenolol Versus Losartan in Children and Young Adults with Marfan Syndrome
Ronald V. Lacro, MD, et al.
Martine Gilard, MD, PhD, et al.
Anna Axelsson, MD, et al.
Impact of a Multidisciplinary Management Program on Recurrent Hospitalization and Mortality in Older Individuals With Chronic Atrial Fibrillation: A Multi-Center Randomized Trial
Simon Stewart, MD, et al.
Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: a randomized clinical trial
Yasuo Ikeda, MD, et al.
John J.V. McMurray, MD, et al.
FACTOR-64 Randomized Clinical Trial
Joseph B. Muhlestein, MD, et al.
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
Eugene Braunwald, MD, et al.
Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the TAXUS Liberte Paclitaxel- Eluting Coronary Stent
Kirk N. Garratt, MD, et al.
Six versus Twelve Months of Clopidogrel Therapy After Drug-Eluting Stenting - the Randomized, Double-Blind, Placebo-Controlled ISAR-SAFE Trial
Stefanie Schulz-Schupke, MD, et al.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

New Data From EVOLVE Clinical Program Demonstrate SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance Endpoints

Toshiba Enhances Radiation Dose Tracking System on Infinix

Medtronic Bifurcated Endurant IIs AAA Stent Graft Launched in Europe and United States

SVS and SIR to Initiate Large-Scale PRESERVE Study of IVC Filters in 2015

Zoll to Acquire Philips’ InnerCool Business

Enrollment Underway in BEST-CLI Randomized Trial

Aptus Heli-FX EndoAnchor System to Be Distributed by Maquet in United Kingdom

Endologix Completes Enrollment in the Nellix EVAS FORWARD-IDE Clinical Trial

CSI’s COAST Study Begins Enrollment in Japan

Abbott Enters Electrophysiology Market With Acquisition of Topera

Hansen Medical Launches the Sensei X2 Robotic System

Medtronic Launches Resolute Onyx DES After CE Mark Approval

Venous Indication Approved for Cardinal Health’s MynxGrip Vascular Closure Device

Occlutech Paravalvular Leak Closure Device Approved in Europe

IDE Approved for Trial of Neovasc’s Tiara Transcatheter Mitral Valve

FDA Approves Bracco Diagnostics’ Lumason Ultrasound Contrast Agent

Merit Medical Unveils ThinkRadial Website and Educational Initiative

InspireMD Resumes MGuard Prime Sales and Prioritizes DES and Carotid - New Product Programs

C.R. Bard announces FDA approval of Lutonix 035 drug coated balloon catheter

Covidien Begins Two Neurovascular Clinical Trials

Endologix Completes Enrollment in EVAS FORWARD—GLOBAL Registry of Nellix System

LEOPARD to Compare Endologix AFX System to Other Commercially Available EVAR Devices

CFI Medical’s Zero-Gravity Suspended Radiation Protection System Approved in Europe
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb